Bioengineering of coagulation factor VIII for efficient expression through elimination of a dispensable disulfide loop by Selvaraj, S. R. et al.
ORIGINAL ARTICLE
Bioengineering of coagulation factor VIII for efficient
expression through elimination of a dispensable disulfide loop
S . R . SELVARAJ ,* A. N . SCHELLER ,* H. Z . MIAO,* R . J . KAUFMAN and S . W. P IPE*
*Department of Pediatrics and Communicable Diseases, University of Michigan Medical Center, Ann Arbor, MI; and Center for Neuroscience,
Aging and Stem Cell Research, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA
To cite this article: Selvaraj SR, Scheller AN, Miao HZ, Kaufman RJ, Pipe SW. Bioengineering of coagulation factor VIII for efficient expression
through elimination of a dispensable disulfide loop. J Thromb Haemost 2012; 10: 107–15.
Summary. Background: Heterologous expression of factor
VIII (FVIII) is about two to three orders of magnitude lower
than similarly sized proteins. Bioengineering strategies aimed at
diﬀerent structural and biochemical attributes of FVIII have
been successful in enhancing its expression levels. Objec-
tive: Disulﬁde bonds are vital to the proper folding, secretion
and stability of most secretory proteins. In an eﬀort to explore
additional targeted bioengineering approaches, the role of
disulﬁde bonds in FVIII secretion and function was probed in
this study. Methods and Results: Single and paired cysteine
mutants were generated by substituting with serine or glycine
residues and analyzed by transient transfection into COS-1 and
CHO cells. Seven of the eight disulﬁde bonds in FVIII were
found to be indispensable for proper secretion and function.
However, elimination of the disulﬁde bond formed by C1899
and C1903 within the conserved A3 domain improved the
secretion of FVIII. The addition of the C1899G/C1903G
mutations to apreviouslydescribedFVIII variant, 226/N6,with
high secretion eﬃciency increased its secretion by 2.2-fold.
Finally, the addition of the A1-domain mutation, F309S, in
conjunction with the disulﬁde mutation had an additive eﬀect,
resulting in a net improvement in secretion of between 35 and
45-fold higher than wild-type FVIII in CHO
cells. Conclusion: Such combined targeted bioengineering
strategies may facilitate more eﬃcient production of recombi-
nant FVIII and contribute toward low-cost factor replacement
therapy for hemophilia A.
Keywords: bioengineering, disulﬁde bonds, factor VIII, hemo-
philia A, secretion.
Introduction
Coagulation factor VIII (FVIII), a large plasma glycoprotein
cofactor, performs a critical role in the intrinsic blood
coagulation pathway [1]. A quantitative or qualitative deﬁ-
ciency of this protein results in the inherited bleeding
disorder, hemophilia A, affecting 1 in 5000 males. The
mainstay of treatment for this lifelong bleeding disorder is
FVIII replacement, primarily with recombinantly-derived
protein [2].
A major obstacle to universal implementation of low-cost
replacement therapy is the inherent limitation of commercial
recombinant FVIII (rFVIII) production because its expression
is two to three orders of magnitude lower than that of other
comparably sized proteins in heterologous systems [3]. The
cost of rFVIII therapy is high owing to the expense of
production, puriﬁcation and formulation. In addition, the
requirement of specialized centralized production and distri-
bution of rFVIII has limited its availability to developing and
third world countries [4]. The high costs associated with
commercial rFVIII production are for the most part attrib-
uted to several biochemical characteristics of the recombinant
protein. Inefﬁcient expression of the mRNA [3,5,6] coupled
with misfolding and degradation of a sizeable portion of the
primary translation product [7,8] and retention of FVIII
within the endoplasmic reticulum (ER) through interaction
with several ER chaperones [9–12] contribute signiﬁcantly to
the low expression levels of rFVIII in heterologous systems.
Furthermore, a facilitated transport mechanism comprising
the mannose-binding lectin LMAN1 and MCFD2 has been
shown to be required for efﬁcient transport of FVIII from the
ER to the Golgi [13–17]. FVIII also requires stabilization by
von Willebrand factor (VWF) upon secretion from the cell
[18].
Elucidation of the structure, function and secretion path-
way of FVIII has provided important insights that have aided
in designing and developing bioengineered forms of rFVIII
with improved secretion efﬁciency. Because the B-domain of
FVIII was found to be dispensable for its co-factor activity
[19], a B-domain-deleted (BDD)-FVIII was developed that
resulted in a 17-fold increase in mRNA levels but registered
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only a modest 30% increase in protein secretion, suggesting
other intracellular limitations to secretion were in play [20].
An A1 domain mutation F309S that was introduced into
FVIII to overcome the retention in the ER through
association with BiP increased secretion 3-fold and reduced
ATP requirement for secretion [21]. The requirement for
facilitated transport of FVIII by the LMAN1/MCFD2
complex by interacting primarily through the mannose
residues on N-linked oligosaccharides within its B-domain
[22] has led to the development of a bioengineered FVIII
variant, 226/N6, wherein the addition of a small portion of
native B-domain to BDD-FVIII led to a 5–10-fold improve-
ment in secretion [23]. Introduction of the A1-domain
mutation F309S further enhanced secretion to about 15–20-
fold over BDD-FVIII.
Despite these signiﬁcant advances, the huge divide between
rates of expression of FVIII compared with other similarly
sized proteins in heterologous systems still persists. A large
proportion of current research is focused on identifying and
exploring new targets for FVIII bioengineering. Some of the
unexplored areas of FVIII structure from a bioengineering
perspective include post-translational modiﬁcations such as
asparagine (N)-linked glycosylation outside of the B-domain,
O-glycosylation and disulﬁde bond formation among others.
Disulﬁde bonds are generally considered vital to the structural
stability of most secreted and membrane proteins and play a
crucial role in the quality control and secretion of proteins
from the ER [24,25]. However, in certain proteins, speciﬁc
disulﬁde loops have been identiﬁed as dispensable to the
proper folding, secretion and functionality of the protein.
Additionally, elimination of these loops has contributed to
increased secretion efﬁciency in these proteins. Examples
include human lysozyme [26,27] and human chorionic gona-
dotropin a and b-subunit [28,29]. FVIII has eight disulﬁde
bonds in its structure [30] (Fig. 1) but the effect of these on
FVIII expression has not been characterized to date.
In this report, we have systematically analyzed the eight
disulﬁde bonds of FVIII and characterized their role in its
secretion and function.While themajority of its disulﬁde bonds
were indispensable for the proper secretion and function of
FVIII, one loop was found to be non-essential and its
elimination improved FVIII secretion. A further increment in
secretion was observed when this disulﬁde mutation was
introduced into the 226/N6 variant carrying the previously
described A1 domain mutation, F309S, suggesting that this
might be yet another independent mechanism that limits the
efﬁcient heterologous expression of FVIII.
Materials and methods
FVIII-deﬁcient and normal pooled human plasma were
obtained from George King Biomedical (Overland Park, KS,
USA). Activated partial thromboplastin (automated aPTT
reagent) and CaCl2 were purchased from bioMerieux Inc.
(Durham, NC, USA). Dulbecco modiﬁed Eagle medium
(DMEM), fetal bovine serum and other tissue culture reagents
were purchased from Gibco BRL (Gaithersburg, MD, USA).
COAMATIC was purchased from DiaPharma (West Chester,
OH, USA). F8C-EIA was purchased from Afﬁnity Biologicals
Inc. (Ancaster, ON, Canada). FuGENE-6 transfection reagent
and restriction enzymes were purchased from Roche Applied
Science (Indianapolis, IN, USA). The Quikchange XL-site
directed mutagenesis kit was purchased from Stratagene (La
Jolla, CA, USA).
Plasmid mutagenesis
The mammalian expression vector, pMT-2 containing the full
length human FVIII cDNA (NM_000132), designated as WT-
FVIII, was subjected tomutagenesis using theQuikchangeXL-
site directed mutagenesis kit to generate single and paired
mutants of cysteines involved in disulﬁde bond formation. The
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Fig. 1. Factor VIII has eight disulﬁde bonds in its mature form. The A1 and A2 domains of the heavy chain and A3 domain of the light chain
contain two disulﬁde bonds each while the C1 and C2 domains of the light chain contain one disulﬁde bond each (A). The positions of the free and
disulﬁde paired cysteines of FVIII are shown in yellow in this X-ray crystal structure representation (courtesy of Dr. B. L. Stoddard, Fred Hutchinson
Cancer Research Center, Seattle, WA) (B). Seven of these disulﬁdes are buried in the hydrophobic core whereas the disulﬁde bridge between C1899 and
C1903 is exposed to the surface.
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cysteine residue was mutated to either glycine or serine in each
case. All mutant plasmids were veriﬁed by restriction enzyme
digestion and DNA sequence analysis. The C1899G/C1903G
double mutant within 226/N6 [23] was similarly generated and
designated as 226/N6-DM. The 226/N6-DM-F309S construct
was generatedby subcloning theSpeI-KpnI fragmentof plasmid
Phe309Ser [21] into the 226/N6-DM plasmid as described
previously.
Transient cell transfection and analysis
The wild-type and mutant plasmid constructs were transfected
into Chinese hamster ovary (CHO) cells using FuGENE-6
transfection reagent as per the manufacturers guidelines.
Transfections into COS-1 cells were carried out by the
diethylaminoethanol (DEAE) - dextran method [31]. Condi-
tioned medium was harvested at 60–70 h post-transfection.
Stable expression of 226/N6 disulfide mutants in CHO cells
226/N6, 226/N6-F309S, 226/N6-DM and 226/N6-DM-F309S
cDNA inserts in pMT2 were excised with XhoI and SalI and
inserted into a modiﬁed mammalian expression vector
pDEF38 [32] at the XhoI site. The resulting plasmids were
linearized with FspI prior to electroporation into DHFR-null
CHODUKX-K1 cells using amaxa cell lineNucleofectorKit
T (Lonza) with 0.5 lg plasmid into 5 · 106 cells for growth in
MEM alpha (Invitrogen) 10% heat-inactivated FBS (Invitro-
gen) supplemented with ADT (1 lg mL)1 each of Adenosine,
Deoxyadenosine, Thymidine). After 48 h, the cells from a
single 10-cm dish were diluted into 15 10-cm dishes, for
selection of growth in MEM alpha 10% heat-inactivated
dialyzed-FBS (Invitrogen) lacking the ADT supplement. After
10–14 days, individual colonies autotrophic for DHFR were
picked and transferred into wells of a 96-well dish. After three
more weeks to allow expansion of the colonies, the highest
expressing colonies at this point were secreting FVIII at around
1 U mL)1. From each FVIII variant, three expressing colonies
were combined into a pool for each variant for selection of
growth in 50 nmol L)1 MTX (methotrexate [Calbiochem]) in
MEM alpha-10% FBS as had been done above (dialyzed FBS
lacking ADT supplements). After allowing colonies to appear,
picking 96 of them, and expanding these, six of 226/N6 and 12
of the other three variants were chosen for study of expression
of FVIII variants. Stably transformed cells growing well in
50 nmol L)1 MTX were plated in 6-cm dishes and allowed to
reach conﬂuence after 4 days. The number of cells was
estimated to be approximately 5 · 106 cells per dish. The cell
culture supernatants collected after 2 days were analyzed using
aPTT and ELISA.
In vivo plasmid expression in a hemophilia A (exon 16 )/))
mouse model by hydrodynamic tail-vein injection
In vivo expression of 226/N6-F309S and 226/N6-DM-F309S
constructs was analyzed in an F8 exon 16 knock-out mouse
model of hemophilia A. Plasmid DNA (100 lg) was diluted in
2.0 mL Lactated Ringers and infused over 10 s into the tail
vein [33,34]. Peripheral blood was collected from the retro-
orbital venous plexus after 24 h and anticoagulated with 3.8%
sodium citrate. Plasma was separated by centrifugation at
2000 g for 20 min and FVIII activity and antigen levels were
analyzed by COAMATIC chromogenic assay and human
FVIII-speciﬁc ELISA, respectively.
Factor VIII assays
An anti-FVIII light chain sandwich enzyme-linked immuno-
sorbent assay (ELISA) was employed to quantify FVIII
antigen levels using a commercial F8C-EIA kit (Afﬁnity
Biologicals) according to themanufacturers recommendations.
FVIII activity was measured by two different methods: (i) a
one-stage aPTT clotting assay on an MLA Electra 750
ﬁbrinometer (Medical Laboratory Automation, Pleasantville,
NY, USA) by reconstitution of human FVIII-deﬁcient plasma.
The FVIII plasma standard was normal pooled plasma
(FACT) from George King Biomedical; (ii) a two-stage
chromogenic method using the COAMATIC assay kit accord-
ing to themanufacturers instructions. The calibration standard
included with this kit is assayed according to the Fourth
International WHO standard.
Statistical analysis
Data are expressed as mean values plus or minus standard
deviation. Statistical analyses were performed by a two-sided
Students t test. Statistical signiﬁcance was established at
P < 0.05.
Results
Seven of eight disulfide bonds are indispensable for FVIII
secretion and function
In order to study the role of each of the eight disulﬁde bonds of
FVIII in its secretion and function, we generated single and
paired cysteine mutants by mutating them to either serines or
glycines and analyzed them by transient transfection in COS-1
and CHO cells. FVIII antigen and one-stage activity assays
performed on conditioned media harvested 60–70 h post-
transfection revealed that of the eight paired double cysteine
mutants, sevenwerefoundtoberetainedintracellularlywhile the
double mutants, C1899/1903S (Fig. 2A,C) and C1899/1903G
(Fig. 2B,D), showed an improved secretion over and above the
wild-type FVIII levels. Similar analysis of the 16 single cysteine
mutants showed that 15 of them were retained intracellularly
withantigenandactivity levelswell belowbackground readings.
Incontrast, theC1903SandC1903Gmutantswere secretedwith
antigen levels of about 70–80% of that of wild-type FVIII and
the proteins were fully functional (data not shown).
The C1899/1903S double mutant displayed, on average, a
1.2-fold higher secretion than wild-type FVIII in COS-1 cells,
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while it was secreted at about 1.35-fold higher than the wild-
type FVIII in CHO cells. The C1899/1903G double mutant on
the other hand exhibited, on average, a 1.3 and 1.6-fold higher
secretion in COS-1 and CHO cells, respectively. These results
were reproducible and consistent in at least ﬁve separate
transfection experiments with two different independently
isolated mutant clones. The activity of the double mutant, as
witnessed from both one-stage (135–168 mU mL)1) and two-
stage assays (121–149 mU mL)1) correlated with the higher
antigen levels (22.8–31.1 ng mL)1). A similar modest improve-
ment in secretion was observed for the C1899/C1903 double
mutants in the BDD-FVIII backbone as well (data not shown).
C1899/1903G double mutant displays higher secretion in
226/N6 backbone
As both C1899/1903S and C1899/1903G mutants performed
similarly and with the C1899/1903G mutant displaying a
slightly better secretion potential, we next tested if this disulﬁde
mutation was capable of further enhancing secretion in 226/
N6, the bioengineered variant with superior secretion efﬁ-
ciency. To achieve this, we recreated the C1899/1903G double
mutant in the 226/N6 backbone and performed transfection
analysis in COS-1 and CHO cells. The activity (one-stage and
two-stage) and the antigen levels were measured in conditioned
media 60–70 h post-transfection and were compared with 226/
N6-FVIII. The results showed that the disulﬁde mutation
augmented secretion of the 226/N6 variant by about 1.6-fold in
COS-1 cells (Fig. 3A) and by about 2.2-fold (P < 0.05) in
CHO cells (Fig. 3B). Quantitation of FVIII in cell extracts by
ELISA revealed that 226/N6 and 226/N6-DM were expressed
at similar levels intracellularly (data not shown), suggesting a
secretion advantage for the disulﬁde mutant. These ﬁndings
were reproducible and consistent across multiple independent
transfection experiments (n ‡ 6).
Additive effect of A1 domain mutation (F309S) on 226/N6-
DM secretion
Retention of FVIII in the ER through interaction with BiP is
one of the major hurdles for efﬁcient secretion. The previously
described A1 domain point mutation, F309S, resulted in about
2-fold higher expression of both the full length FVIII and 226/
N6 variant in cells [23]. We therefore hypothesized that
addition of this mutation would further improve secretion of
226/N6-DM. We generated the 226/N6-DM-F309S hybrid
construct through a sub-cloning strategy described earlier and
performed transient transfection into COS-1 and CHO cells.
Conditioned media harvested 60–70 h post-transfection were
analyzed for expression by activity (one-stage and two-stage)
and antigen assays. Results were expressed relative to 226/N6
transfected in parallel. The 226/N6-DM-F309S construct was
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Fig. 2. Seven of the eight disulﬁde bonds in FVIII are essential for the proper secretion and activity of the protein. Paired double cysteine mutants
containing cysteine to serine modiﬁcations were transiently expressed in COS-1 cells (Panel A) and CHO cells (Panels C). Double cysteine mutants
consisting of cysteine to glycine changes were similarly expressed in COS-1 (Panel B) and CHO (Panel D) cells. FVIII antigen (ng mL)1) ( ) and one-stage
activity (mU mL)1) (h) levels weremeasured by ELISA and aPTT, respectively, and are presented here as a percentage of wild-type FVIII. The assays were
performed on conditioned medium 60–70 h post-transfection. Data presented are representative of several independent transfection experiments (n ‡ 6)
and the error bars where shown represent the standard deviation.
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secreted at an even higher level, resulting in a net increase of
about 3.2-fold over 226/N6 in COS-1 cells (Fig. 4A) and close
to 4.1-fold in CHO cells (Fig. 4B) (P < 0.05). Thus, there was
an additive effect of the A1-domain mutation, F309S, to the
secretion enhancement conferred by the disulﬁde mutation
within the 226/N6 backbone. These results were similarly
consistent and reproducible across several independent trans-
fection experiments both in COS-1 and CHO cells.
Stable expression of 226/N6-DM and 226/N6-DM-F309S
within CHO cells
Chinese hamster ovary cell lines stably expressing 226/N6-DM
and 236/N6-DM-F309S were prepared as described under
Methods. Comparison of the high expressing clones of 226/N6,
226/N6-DM, 226/N6-F309S and 226/N6-DM-F309S revealed
that the secretion advantage conferred by the C1899/1903G
disulﬁde mutation was preserved in the stably expressing CHO
cell line as well. Average FVIII antigen levels of 6.3, 11.9, 12.9
and 23.8 lg mL)1 were obtained for 226/N6, 226/N6-DM,
226/N6-F309S and 226/N6-DM-F309S, respectively. The
average FVIII activity levels, as measured by an aPTT assay,
for these four constructs were 15.7, 31.3, 32.3 and
54.8 U mL)1, respectively. On average, the 226/N6-DM var-
iant demonstrated a 1.8–2.0-fold higher secretion over 226/N6
and the 226/N6-DM-F309S variant exhibited a 1.7–1.85-fold
improvement in secretion over 226/N6-F309S (Fig. 5).
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In vivo expression of 226/N6-DM-F309S
In order to test whether the secretion improvement observed
for the disulﬁde mutant in COS-1 and CHO cells would also
extend to an in vivo heterologous expression system,we induced
transient expression of 226/N6-F309S and 226/N6-DM-F309S
constructs in the liver of hemophilia A (F8)/)) using a
hydrodynamic tail-vein injection of plasmid DNA as described
earlier. A FVIII-speciﬁc ELISA showed an average antigen
level of 1.05 lg mL)1 for 226/N6-F309S and 1.8 lg mL)1 for
226/N6-DM-F309S (Fig. 6A). The FVIII activity levels mea-
sured by the COAMATIC chromogenic assay were, on
average, 7.8 U mL)1 for 226/N6-F309S and 13.2 U mL)1 for
226/N6-DM-F309S (Fig. 6B). These values suggested  1.7-
fold higher expression levels of 226/N6-DM-F309S over 226/
N6-F309S, indicating that the secretion enhancement of the
disulﬁde mutant was reproducible in vivo as well. The speciﬁc
activity of 226/N6-F309S (7428.57 U mg)1) was similar to 226/
N6-DM-F309S (7333.33 U mg)1).
Bioengineering results in synergistic improvement in secretion
of FVIII
Incorporation of the disulﬁde mutation in previously bioengi-
neered FVIII variants with higher expression efﬁciency further
boosts secretion with synergistic effect. Data shown in Fig. 7
were obtained from comparing expression levels of 226/N6-
DM and 226/N6-DM-F309S constructs with wild-type FVIII
from multiple transfection experiments in CHO cells. Incor-
poration of these mutations within 226/N6 led to a cumulative
effect, resulting overall in a 35–45-fold higher secretion than
wild-type FVIII in CHO cells, suggesting that such combined
targeted bioengineering strategies may facilitate more efﬁcient
production of rFVIII and contribute toward low-cost replace-
ment therapy.
Discussion
With the exception of the report by McMullen et al. [30]
identifying the locations of disulﬁde bonds and free cysteines,
there havent been any other studies that have focused on the
role of disulﬁde bonds within FVIII. This report is the ﬁrst to
systematically analyze the role of each individual disulﬁde bond
in the secretion and function of FVIII. While disulﬁde bridges
are generally indispensable for the proper folding, assembly,
secretion and function of most disulﬁde containing proteins,
there have been reports of certain exceptions, as in the case of
human lysozyme [26,27] and human chorionic gonadotropin
alpha [29] and beta [28] subunits, wherein mutation of a
particular cysteine residue involved in disulﬁde bonding or
elimination of a disulﬁde loop improved secretion efﬁciency.
We therefore tested whether a similar exception may exist
within a complex, multidomain protein such as FVIII.
We observed that 15 of the 16 cysteine residues involved in
seven disulﬁde bonds were indispensable and mutation of these
residues to serine or glycine resulted in complete intracellular
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Fig. 6. C1899/1903G disulﬁde mutation confers secretion advantage in
vivo in a hemophilia A mouse model. FVIII antigen (Panel A) and activity
(Panel B) in the plasma of hemophilia Amice weremeasured by an ELISA
and a COAMATIC chromogenic assay, respectively, following transient
expression of 226/N6-F309S and 226/N6-DM-F309S constructs by
hydrodynamic tail vein injection as described under Methods. Data pre-
sented (s) represent multiple independent expression studies (n ‡ 5) with
the mean indicated by a bar. *P < 0.05.
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retention of the protein. All of these cysteines are buried and
form core disulﬁde bonds that are essential for the stability of
the protein. C1899 and C1903 are the only two cysteine
residues that are exposed to the surface. These ﬁndings were
mostly consistent with the phenotype of patient missense
mutations reported in the database the of Hemophilia A
Mutation, Structure, Test and Resource Site (HAMSTeRS)
available on the internet (URL: http://hadb.org.uk/) as well as
from newer reports in the literature. Therefore, in essence, this
study also provides a mechanistic basis for the clinical
phenotype of missense mutations of cysteine residues involved
in FVIII disulﬁde bonding, reported so far.
There have been no clinical reports so far of missense
mutations of either C1899 or C1903 that are causative of
hemophilia A in patients. The only alteration reported with
C1903 in the HAMSTeRS database is that of a nonsense
mutation resulting in a truncated protein causing severe
hemophilia A. This further strengthens the argument that
these two cysteines and the disulﬁde bond they form might be
dispensable to the proper folding, secretion and function of
FVIII. In addition, two missense mutations of C1903, namely
C1903S and C1903W, have been recorded in the National
Center for Biotechnology Information (NCBI) database of
single nucleotide polymorphisms (SNPs) (http://www.ncbi.
nlm.nih.gov/projects/SNP/snp_ref.cgi?locusId=2157). Both
these entries have been validated by multiple, independent
submissions to the refSNP cluster and have been genotyped by
the HapMap project. This is quite consistent with our
observations of the C1903S and C1903G single cysteine
mutants that were secreted at levels of about 70–80% of
wild-type FVIII in COS-1 and CHO cells. Interestingly, the
C1899G single mutant was retained completely yet the double
mutant 1899–1903 was found to be secreted more efﬁciently
than the wild-type FVIII. Precedents for pairing cysteines
behaving differently in the context of the folding and secretion
of a protein can be found in the examples of human lysozyme
[35] and human chorionic gonadotropin b subunit [28]. It is
likely that the free thiol at C1903 in the C1899G mutant may
hinder secretion by interacting with other free thiols in FVIII.
Further insights regarding the enhanced secretion of the
1899–1903 double mutant can be gained from the structural
comparison of FVIII and its coagulation factor homolog, FV.
Despite sharing an identical domain structure and approxi-
mately 40% amino acid identity within their A and C domains,
FV is secreted 10–20-fold higher than FVIII [36]. A comparison
of the disulﬁde bonds of FVIII and FV reveals that seven of the
eight disulﬁde bonds present in FVIII are highly conserved in
FV but interestingly, FV lacks a disulﬁde loop in the
homologous position to the C1899-C1903 disulﬁde bridge in
FVIII [30].We hypothesize that the elimination of this disulﬁde
loop improves secretion of FVIII through alterations in the
molecular ﬂexibilities in the secondary or tertiary structure.
This, along with other factors such as little or no binding of FV
to BiP [36], might explain the huge difference in secretion of
these two structurally similar proteins.
We had also hypothesized that elimination of this non-
essential disulﬁde bond would overcome a unique mechanism
limiting FVIII secretion efﬁciency that had previously been
explored with other bioengineered FVIII variants. Thus,
combining this targeted strategy with other previously
described bioengineered variants with improved secretion
efﬁciency could have an additive effect. In support of this,
introduction of this disulﬁde mutation into 226/N6 produced a
further boost in secretion efﬁciency. The higher secretion
efﬁciency of 226/N6 has been attributed to its optimization of
the LMAN-1/MCFD2 facilitated ER-Golgi transport through
the N-linked oligosaccharides within its short B-domain spacer
[23]. Additionally, the incorporation of F309S, the A1 domain
mutation that has been shown earlier to improve secretion by
diminishing FVIII association with BiP and reducing its ATP
dependence [21], into this hybrid construct resulted in addi-
tional improvement in secretion. This secretion enhancement
was consistently observed both during transient as well as
stable expression in cell lines. Furthermore, the secretion
advantage conferred by the disulﬁde mutation could
also be reproduced in vivo in a hemophilia A (F8)/)) mouse
model.
Overall, this study provides new insights into the role of
disulﬁde bonds in the folding, secretion and function of FVIII.
Such insights are crucial in devising novel bioengineering
strategies to improve commercial rFVIII production. These
results also provide impetus to target other previously unex-
plored structural elements of FVIII such as N-linked glycosyl-
ation and other post-translational modiﬁcations to ﬁndways to
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Fig. 7. Bioengineering strategies lead to synergistic improvements in FVIII secretion eﬃciency. Data obtained by comparing expression levels of 226/N6-
DM and 226/N6-DM-F309S constructs to full length wild-type FVIII (WT-FVIII) from a series of several independent transient transfection experiments
in CHO cells. Data are presented as fold-WT-FVIII. Error bars represent the standard deviation. *P < 0.05.
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improve secretion. However, because many of these strategies
involve the introduction of missense mutations to the native
FVIII sequence, such variants will need to be tested for their
potential in creating neoantigenic sites on FVIII that might
lead to inhibitor formation in patients.
Ward et al. [37] recently reported a 29–44-fold increase in
expression of FVIII codon-optimized for expression in Homo
sapiens. Though the mechanism is unclear, this approach most
likely targets transcriptional and translational hindrances to
efﬁcient FVIII expression. We hypothesize that targeting post-
translational modiﬁcations such as disulﬁde bonding, as we
have done in the present study, could provide opportunities
for improved expression efﬁciency that are additive to such
enhancements to transcriptional and translational regulation
of FVIII expression. A combination of targeted bioengineer-
ing techniques, as described in this study, has made it possible
to attain about 35–45-fold higher secretion than wild-type
FVIII in mammalian cells. This clearly emphasizes the
importance of such bioengineering methodology in achieving
the ultimate goal of maximizing FVIII yield and reducing the
overall costs of manufacturing, which would make FVIII
therapeutics more affordable and accessible to the global
hemophilia population.
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